This study proposes the Drosophila melanogaster parabss1 mutant as a valid and manageable in vivo model for chronic nociception. By exhibiting selective hypersensitivity, resistance to conventional treatment and sensitivity to cannabidiol, this model provides a cost-effective and ethically favourable platform for the preclinical screening of novel analgesics that target sodium channel dysfunctions. This study opens a new avenue for translational pain research and aligns with the ongoing demand for alternative animal models in pain therapeutic development.
Malta et al. (Tue,) studied this question.